N Engl J Med 373(23):22472257 Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL et al (2018) Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Ayuda a neutralizar los radicales libres, molculas inestables que pueden daar las clulas y acelerar el proceso de envejecimiento
Xu et al., 2002), heavy metals (Rai et al., 2011), phosphate starvation (Shukla et al., 2015), salt (Reymond et al., 2000)
In clinical trials, average body-weight reduction ranged between 1015% , but real-world users often see lower results
A part of Watch Medier Senior Medical Specialist, Therapeutic Areas - Global Clinical Development Senior P&C Business Partner International Product Manager, MEQU/1947 Director, Drug Safety Operations Senior Safety Manager Medical Writer responsible for Clinical Disclosure Regulatory Affairs Manager, Chr
Lancet (London England) (2018) 392(10157):151929